BioCentury | Sep 14, 2018
Finance

Coda’s chemogenetic control

...who joined Coda in conjunction with the A round, was previously CEO of obesity company Orexigen Therapeutics Inc....
BioCentury | Sep 14, 2018
Financial News

MPM, Versant launch gene therapy play Coda

...joined Coda in conjunction with the financing, was previously CEO and director of obesity company Orexigen Therapeutics Inc....
BioCentury | Sep 12, 2018
Financial News

MPM, Versant launch gene therapy play Coda

...joined Coda in conjunction with the financing, was previously CEO and director of obesity company Orexigen Therapeutics Inc....
BioCentury | Aug 9, 2018
Company News

Management tracks: Grail, Celyad, Hua

...is succeeded by Thomas Cannell, who was COO and president of global commercial products at Orexigen Therapeutics Inc....
BioCentury | Apr 27, 2018
Company News

Orexigen accepts $75M stalking horse bid

...On April 23, Orexigen Therapeutics Inc. (NASDAQ:OREX) accepted a $75 million cash bid from an investor group including...
...Holdings Inc. (NASDAQ:PTX) to acquire Orexigen assets including worldwide rights to obesity drug Contrave naltrexone/bupropion. Orexigen...
...NASDAQ:PTX), Morristown, N.J. Orexigen Therapeutics Inc. (NASDAQ:OREX), La Jolla, Calif. Business: Endocrine/Metabolic Allison Johnson Contrave, Mysimba, naltrexone sr/bupropion sr (NB32) Orexigen Therapeutics Inc. Pernix...
BioCentury | Mar 16, 2018
Financial News

Orexigen files for bankruptcy

...no later than May 24. It hopes to have a sale concluded by July 2. Orexigen's...
...U.S. as Contrave in 2014 and in the EU as Mysimba in 2015. Last year Orexigen...
...fixed-dose combination of naltrexone sustained release (SR) and bupropion SR. Orexigen Therapeutics Inc. (NASDAQ:OREX), La Jolla, Calif. Mary Romeo bupropion Contrave Mysimba Orexigen Therapeutics Inc. Takeda...
BioCentury | Sep 21, 2017
Targets & Mechanisms

Appetite for GFRAL

...that target neurotransmitter systems: Arena Pharmaceuticals Inc. ’s Belviq lorcaserin, a serotonin 5-HT2C receptor agonist; Orexigen Therapeutics Inc....
...Francisco, Calif. Novartis AG (NYSE:NVS; SIX:NOVN), Basel, Switzerland Novo Nordisk A/S (CSE:NOVOB; NYSE:NVO), Bagsværd, Denmark Orexigen Therapeutics Inc....
BioCentury | May 9, 2017
Politics & Policy

PhRMA revises eligibility criteria, cutting membership

...AMAG Pharmaceuticals Inc. (NASDAQ:AMAG), Horizon Pharma plc (NASDAQ:HZNP), Jazz Pharmaceuticals plc (NASDAQ:JAZZ), Mallinckrodt plc (NYSE:MNK), Orexigen Therapeutics Inc....
BioCentury | Sep 13, 2016
Top Story

Competing drug pricing visions aired

...John Maraganore, CEO of Alnylam Pharmaceuticals Inc. (NASDAQ:ALNY); and Michael Narachi, president and CEO of Orexigen Therapeutics Inc....
BioCentury | Sep 5, 2016
Company News

Orexigen, Valeant Pharmaceuticals deal

...Orexigen’s Orexigen Therapeutics Ireland Ltd. subsidiary granted Valeant’s Valeant Canada L.P. subsidiary exclusive rights to develop...
...in Canada. Valeant said it plans to submit an NDA in Canada by January 2017. Orexigen...
...Valeant for an undisclosed transfer fee and is eligible for undisclosed regulatory and sales milestones. Orexigen...
Items per page:
1 - 10 of 390
BioCentury | Sep 14, 2018
Finance

Coda’s chemogenetic control

...who joined Coda in conjunction with the A round, was previously CEO of obesity company Orexigen Therapeutics Inc....
BioCentury | Sep 14, 2018
Financial News

MPM, Versant launch gene therapy play Coda

...joined Coda in conjunction with the financing, was previously CEO and director of obesity company Orexigen Therapeutics Inc....
BioCentury | Sep 12, 2018
Financial News

MPM, Versant launch gene therapy play Coda

...joined Coda in conjunction with the financing, was previously CEO and director of obesity company Orexigen Therapeutics Inc....
BioCentury | Aug 9, 2018
Company News

Management tracks: Grail, Celyad, Hua

...is succeeded by Thomas Cannell, who was COO and president of global commercial products at Orexigen Therapeutics Inc....
BioCentury | Apr 27, 2018
Company News

Orexigen accepts $75M stalking horse bid

...On April 23, Orexigen Therapeutics Inc. (NASDAQ:OREX) accepted a $75 million cash bid from an investor group including...
...Holdings Inc. (NASDAQ:PTX) to acquire Orexigen assets including worldwide rights to obesity drug Contrave naltrexone/bupropion. Orexigen...
...NASDAQ:PTX), Morristown, N.J. Orexigen Therapeutics Inc. (NASDAQ:OREX), La Jolla, Calif. Business: Endocrine/Metabolic Allison Johnson Contrave, Mysimba, naltrexone sr/bupropion sr (NB32) Orexigen Therapeutics Inc. Pernix...
BioCentury | Mar 16, 2018
Financial News

Orexigen files for bankruptcy

...no later than May 24. It hopes to have a sale concluded by July 2. Orexigen's...
...U.S. as Contrave in 2014 and in the EU as Mysimba in 2015. Last year Orexigen...
...fixed-dose combination of naltrexone sustained release (SR) and bupropion SR. Orexigen Therapeutics Inc. (NASDAQ:OREX), La Jolla, Calif. Mary Romeo bupropion Contrave Mysimba Orexigen Therapeutics Inc. Takeda...
BioCentury | Sep 21, 2017
Targets & Mechanisms

Appetite for GFRAL

...that target neurotransmitter systems: Arena Pharmaceuticals Inc. ’s Belviq lorcaserin, a serotonin 5-HT2C receptor agonist; Orexigen Therapeutics Inc....
...Francisco, Calif. Novartis AG (NYSE:NVS; SIX:NOVN), Basel, Switzerland Novo Nordisk A/S (CSE:NOVOB; NYSE:NVO), Bagsværd, Denmark Orexigen Therapeutics Inc....
BioCentury | May 9, 2017
Politics & Policy

PhRMA revises eligibility criteria, cutting membership

...AMAG Pharmaceuticals Inc. (NASDAQ:AMAG), Horizon Pharma plc (NASDAQ:HZNP), Jazz Pharmaceuticals plc (NASDAQ:JAZZ), Mallinckrodt plc (NYSE:MNK), Orexigen Therapeutics Inc....
BioCentury | Sep 13, 2016
Top Story

Competing drug pricing visions aired

...John Maraganore, CEO of Alnylam Pharmaceuticals Inc. (NASDAQ:ALNY); and Michael Narachi, president and CEO of Orexigen Therapeutics Inc....
BioCentury | Sep 5, 2016
Company News

Orexigen, Valeant Pharmaceuticals deal

...Orexigen’s Orexigen Therapeutics Ireland Ltd. subsidiary granted Valeant’s Valeant Canada L.P. subsidiary exclusive rights to develop...
...in Canada. Valeant said it plans to submit an NDA in Canada by January 2017. Orexigen...
...Valeant for an undisclosed transfer fee and is eligible for undisclosed regulatory and sales milestones. Orexigen...
Items per page:
1 - 10 of 390